ReviewHuman genetics2018
China: concurring regulation of cross-border genomic data sharing for statist control and individual protection.
Review in Human genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Unlocking the potential of Asian genomic data: a collaborative framework for precision medicine innovation.GigaScience · 2026Review
- Data visiting governance: a conceptual framework.Human genomics · 2025Review
- Governance of cross-border genomic data sharing through a human rights approach.Nature genetics · 2025Review
- Communicating clearly about data sharing in genomics.Human genomics · 2025Review
- A scoping review of human genetic resources management policies and databases in high- and middle-low-income countries.BMC medical ethics · 2025Article
- Article
- Regulatory barriers to US-China collaboration for generative AI development in genomic research.Cell genomics · 2024Article
- Integrating China in the International Consortium for Personalised Medicine: a position paper on innovation and digitalization in Personalized Medicine.BMC public health · 2024Article
- Paradigm Transformation of Global Health Data Regulation: Challenges in Governance and Human Rights Protection of Cross-Border Data Flows.Risk management and healthcare policy · 2024Article
- FAIR human neuroscientific data sharing to advance AI driven research and applications: Legal frameworks and missing metadata standards.Frontiers in genetics · 2023Review
- Review
- Sociotechnical safeguards for genomic data privacy.Nature reviews. Genetics · 2022Review
- Genetic Privacy and Data Protection: A Review of Chinese Direct-to-Consumer Genetic Test Services.Frontiers in genetics · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews the major legal instruments and self-regulations that bear heavily on the cross-border sharing of genomic data in China. It first maps out three overlapping frameworks on genomic data and analyzes their underpinning policy goals. Subsequent sections examine the regulatory approaches with respect to five aspects of responsible use and sharing of genomic data, namely, consent, privacy, security, compatible processing, and oversight. It argues that substantial centralised control exerted by the state is, and would probably remain, the dominant feature of genomic data governance in China, though concerns of individual protection are gaining momentum. Rather than revolving around a simplistic antinomy between privacy preservation and open science, the regulatory landscape is mainly shaped by the tension between government desires for national security, state competitiveness, and public health benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.